Feeds:
Posts
Comments

Archive for the ‘Hormone-refactory’ Category

URO TODAY:  Stopping the enzyme process that allows a prostate tumour to produce androgens could be the key in halting a tumour’s growth, researchers in Texas say. READ MORE>

Prostate cancer advances when tumors become resistant to hormone therapy, which is the standard treatment for patients, and begin producing their own androgens.

Read Full Post »

US NATIONAL CANCER INSTITUTE: Scientists are making progress towards finding a life-extending treatment option for men with metastatic castration-resistant prostate cancer. READ MORE>

Read Full Post »

URO TODAY:  Abiraterone acetate is a promising treatment for advanced prostate cancer patients and is being tested in a Phase III trial for men with progressive castration-resistant prostate cancer who have  not had chemotherapy.

A Phase III trial for patients following prior chemotherapy has been completed and is awaiting analysis. READ MORE>

Read Full Post »

URO TODAY: Activation of the androgen receptor is crucial for prostate cancer growth at all points of the illness, and two new drugs are showing promise in preventing that happen. READ MORE>

Notably, promising activity has been shown in early phase trials by MDV3100, a new anti-androgen designed for activity in prostate cancer model systems with over-expressed androgen receptor, and by abiraterone acetate, a CYP17A inhibitor that blocks steroid biosynthesis in the adrenal gland and possibly within the tumour. Both agents are undergoing phase three testing.

Read Full Post »

URO TODAY: A combination of docetaxel/zoledronic/prednisone in chemotherapy for hormone refractory prostate cancer patients is safe and effective, say Indian researchers. For patients with a Gleason score less than 7, PSA declined more than 50% and those who received more than four cycles had significantly better survival. READ MORE>

Read Full Post »

URO TODAY: Depression and cognitive loss are common in men on hormone therapy for prostate cancer and early treatment with anti-depressants is recommended, according to a paper on HT side effects presented at a conference in Turkey. READ MORE>

Read Full Post »

URO TODAY: Once, chemotherapy (then death) were the only options left for prostate cancer patients on whom hormone therapy stopped working: now new drugs give hope of extended life. READ MORE>

Read Full Post »

MEDICAL NEWS TODAY: A phase 3 clinical trial of the investigational drug MDV3100 for advanced prostate cancer has just begun in the US. READ MORE>

Known as AFFIRM, the trial will evaluate the novel androgen receptor antagonist MDV3100 in men with castration-resistant prostate cancer who were previously treated with .

Read Full Post »

URO TODAY: High levels of testosterone have until recently been regarded as dangerous for prostate cancer patients, but new evidence is emerging that suggests something different. READ MORE>

Provocative new evidence suggests that it is not high serum testosterone that is problematic for prostate cancer, but low serum testosterone that is associated with worrisome cancer features and outcomes, such as high Gleason score, advanced stage of presentation, and increased risk of biochemical recurrence after surgery.

Read Full Post »

URO TODAY: Younger men with high-risk prostate cancer appear to have worse prognosis than older men with similar disease, according to a study of 4000 men receiving hormone treatment. READ MORE>

This, along with the other prognostic variables established in the current study, may help identify candidates for clinical trials evaluating secondary treatments for patients with castrate-resistant disease.

Read Full Post »

Older Posts »

Follow

Get every new post delivered to your Inbox.

Join 26 other followers